QualityStocksNewsBreaks Archives - Page 173 of 1508

MondayJan 13, 2025 11:10 am

QualityStocksNewsBreaks – ROTH Adds Five Strategic Hires to Its Sales and Trading Team

Roth Capital Partners, LLC (“ROTH”) has announced the expansion of its sales and trading team with five seasoned professionals: Todd Trimmer, Nathan Cahill, Ken Hawkins, Matthew Job, and Michael Shea. “These strategic hires exemplify ROTH’s commitment to expanding teams of professionals across departments and advancing our mission to deliver unparalleled service, innovation and growth for clients and stakeholders alike,” said Sagar Sheth, CEO of ROTH, highlighting the significance of these additions. To view the full press release, visit https://ibn.fm/Gp5aV About ROTH ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Its full-service platform provides capital…

MondayJan 13, 2025 7:30 am

QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has priced its public offering of 5,000,000 shares of common stock at $0.85 per share, with gross proceeds expected to total approximately $4.25 million before fees and expenses. The offering, exclusively placed by Ladenburg Thalmann & Co. Inc., is set to close on or around Jan. 10, 2025, subject to customary conditions. Proceeds will support working capital and general corporate purposes. The shares are offered under an effective Form S-3 registration statement, with a final prospectus available on the SEC's website or through Ladenburg Thalmann. To view…

FridayJan 10, 2025 1:45 pm

QualityStocksNewsBreaks – AEON Biopharma Inc. (NYSE: AEON) Secures $20M in Underwritten Public Offering

AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, has announced the closing of its firm commitment underwritten public offering. AEON secured approximately $20.0 million in gross proceeds from the offering, of which it intends to use the net, together with its existing cash, for general corporate purposes and working capital. As detailed in the announcement, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or warrants to cover over-allotments, if any. On Jan. 7, Aegis exercised its over-allotment option with respect…

WednesdayJan 08, 2025 3:07 pm

QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Expanding Exploration, Looks to Replicate Success of Flagship Project

Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a junior exploration company, is positioned to play a critical role amidst growth of copper and gold sectors. “The company’s flagship project, the Storm Copper Project, a joint initiative by Aston Bay and American West Metals, in Nunavut, Canada, made significant advancements in 2024 and is poised for further progress in 2025,” reads a recent article. “The Storm Copper Project has gained attention for its promising assay results and high-grade copper mineralization. Spring/summer 2024 marked another successful exploration season that identified extensive copper zones, demonstrating the project’s potential as a major contributor to global…

WednesdayJan 08, 2025 2:22 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

WednesdayJan 08, 2025 12:30 pm

QualityStocksNewsBreaks – MoneyShow’s Virtual Event to Showcase Actionable Insights, Strategic Investment Playbook

MoneyShow, a leading producer of financial conferences for investors, traders and advisors, today announced the upcoming “Your 2025 Portfolio Playbook Virtual Expo” set to take place on Jan. 28-29, 2025. The fully virtual event will showcase more than 30 renowned speakers and feature world-class educational opportunities, with a focus on crafting a profitable investment strategy for 2025 and beyond. “With policy uncertainty, inflationary pressures and geopolitical instability affecting markets, this event provides sharp and actionable insights from elite financial experts,” said Mike Larson, editor-in-chief at MoneyShow. “Attendees will leave with a comprehensive playbook to navigate unpredictable financial currents and capitalize…

WednesdayJan 08, 2025 9:25 am

QualityStocksNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0) with Code4Cybersecurity to Offer Swiss-Hosted Privacy Solutions

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) announced a partnership with Code4Cybersecurity LLC to distribute its Swiss-hosted privacy and secure communication solutions, including SekurMail, SekurMessenger, and SekurVPN, to Code4’s network of corporate entities, high-net-worth individuals, and entertainment industry VIPs. The collaboration supports Sekur’s strategy of expanding its reach through B2B partnerships and emphasizes its commitment to data security under Switzerland’s strict Federal Act on Data Protection. Sekur’s solutions, designed to counter mass surveillance and enhance user privacy, are offered in two packages: PRIVACY at $25/month or $275/year and PRIVACY+ at $65/month. Code4 CEO Raffi Pamboukian and Sekur CEO…

TuesdayJan 07, 2025 2:15 pm

QualityStocksNewsBreaks – ROTH Expands Team to Continue Driving Innovation in Tech Space

Roth Capital Partners, LLC (“ROTH”) today announced the expansion of its technology team with the addition of Marc Lewis as Managing Director, Head of Technology Investment Banking, and Imtiaz (“Taz”) Koujalgi as Managing Director, Senior Research Analyst, specializing in Enterprise Software. The appointments reinforce ROTH’s commitment to support innovation and growth in the dynamic and rapidly evolving technology sector. “We are pleased to welcome Marc and Taz to the ROTH team as we continue to expand our presence in the rapidly evolving technology sector,” said ROTH’s President and Head of Investment Banking, Aaron Gurewitz. “Marc’s extensive investment banking and portfolio…

TuesdayJan 07, 2025 1:30 pm

QualityStocksNewsBreaks – PSQ Holdings Inc. (NYSE: PSQH) Secures $36.2M in Registered Direct

PSQ Holdings (NYSE: PSQH) is America's leading commerce and payments ecosystem valuing life, family and liberty. The company recently announced its entry into definitive agreements for the purchase and sale of an aggregate of 7,813,931 shares of its Class A common stock, each at a price of $4.63, in a registered direct offering for gross proceeds of approximately $36.2 million. Roth Capital Partners acted as sole placement agent for the offering. For more information, visit https://ibn.fm/fB7c7 About PublicSquare PublicSquare is America’s leading commerce and payments ecosystem, valuing life, family and liberty. PublicSquare operates under three segments: Marketplace, Financial Technology and…

TuesdayJan 07, 2025 1:10 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

Site Search

Company Search

Category: QualityStocksNewsBreaks